SCHEMBL3296378

SCHEMBL3296378

CNCC(=O)C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.47
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 4/20 0.44
CACNA2D1 P54289 2/20 0.44
CACNA1B Q00975 2/20 0.44
CACNB1 Q02641 2/20 0.44
CACNA1C Q13936 2/20 0.44
OPRD1 P41143 1/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
MEN1 O00255 3/20 0.41
CACNA1H O95180 1/20 0.41
LMNA P02545 1/20 0.41
CACNA1G O43497 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14491589 0.86 ALDH1A1 (0.52) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL5461890 0.83 ALDH1A1 (0.51) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL1366519 0.80 ALDH1A1 (0.48) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL24873255 0.80 ALDH1A1 (0.48) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL20594076 0.79 KMT2A (0.57) SLC6A9ALDH1A1KMT2AOPRD1MAPT
SCHEMBL85386 0.77 ALDH1A1 (0.54) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL72964 0.77 CYP3A4 (0.49) SLC6A9ALDH1A1KMT2AOPRD1CNR1
SCHEMBL10619475 0.77 OPRD1 (0.54) SLC6A9ALDH1A1KMT2AOPRD1MAPT
SCHEMBL12499368 0.74 ALDH1A1 (0.51) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B
SCHEMBL4175324 0.74 KMT2A (0.49) SLC6A9ALDH1A1KMT2ACACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737166-B2 Antifungal bicyclic hetero ring compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-06-15 US disclosed
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1932837-A1 BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION Daiichi Sankyo Company, Limited (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides CTPS1, TPP1, STS SLC6A9 1035/4885ALDH1A1 835/4885KMT2A 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.